Brief: Zymeworks Outlines Strategic Priorities And Outlook For 2026

Zymeworks

11/01/2026 23:03

Jan 11 (Reuters) - Zymeworks Inc ZYME.O:

ZYMEWORKS OUTLINES STRATEGIC PRIORITIES AND OUTLOOK FOR 2026

ZYMEWORKS: UP TO $440 MILLION IN MILESTONE PAYMENTS ELIGIBLE TO BE EARNED RELATED TO REGULATORY APPROVALS OF ZIIHERA IN GEA IN UNITED STATES, EUROPE, JAPAN, & CHINA

ZYMEWORKS INC: GLOBAL PHASE 1 CLINICAL TRIAL INVESTIGATING ZW191 IN SOLID TUMORS IS ONGOING WITH DOSE OPTIMIZATION OF ZW191 IN OVARIAN CANCER

Source text: ID:nGNXcMtqc

Further company coverage: ZYME.O

 ((Reuters.Briefs@thomsonreuters.com;))